Your browser doesn't support javascript.
loading
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy.
Kefalas, Panos; Ali, Omar; Jørgensen, Jesper; Merryfield, Nick; Richardson, Tim; Meads, Adam; Mungapen, Laura; Durdy, Matthew.
Afiliação
  • Kefalas P; Health Economics and Market Access Department, The Cell and Gene Therapy Catapult, London, UK.
  • Ali O; Verpora, BioCity, Nottingham, UK.
  • Jørgensen J; Health Economics and Market Access Department, The Cell and Gene Therapy Catapult, London, UK.
  • Merryfield N; Verpora, BioCity, Nottingham, UK.
  • Richardson T; Verpora, BioCity, Nottingham, UK.
  • Meads A; Verpora, BioCity, Nottingham, UK.
  • Mungapen L; Health Economics and Market Access Department, The Cell and Gene Therapy Catapult, London, UK.
  • Durdy M; Business Development Department, Cell and Gene Therapy Catapult, London, UK.
J Mark Access Health Policy ; 6(1): 1511679, 2018.
Article em En | MEDLINE | ID: mdl-30151078
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: J Mark Access Health Policy Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: J Mark Access Health Policy Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido